Last reviewed · How we verify
Cohort 1: JMKX003142 and itraconazole
Cohort 1: JMKX003142 and itraconazole is a Small molecule drug developed by Jemincare. It is currently in Phase 1 development.
At a glance
| Generic name | Cohort 1: JMKX003142 and itraconazole |
|---|---|
| Sponsor | Jemincare |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cohort 1: JMKX003142 and itraconazole CI brief — competitive landscape report
- Cohort 1: JMKX003142 and itraconazole updates RSS · CI watch RSS
- Jemincare portfolio CI
Frequently asked questions about Cohort 1: JMKX003142 and itraconazole
What is Cohort 1: JMKX003142 and itraconazole?
Cohort 1: JMKX003142 and itraconazole is a Small molecule drug developed by Jemincare.
Who makes Cohort 1: JMKX003142 and itraconazole?
Cohort 1: JMKX003142 and itraconazole is developed by Jemincare (see full Jemincare pipeline at /company/jemincare).
What development phase is Cohort 1: JMKX003142 and itraconazole in?
Cohort 1: JMKX003142 and itraconazole is in Phase 1.